CliffBio
small molecule

IDARUBICIN HYDROCHLORIDE

IDARUBICIN HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameIDARUBICIN HYDROCHLORIDE
Active ingredientIDARUBICIN HYDROCHLORIDE
Strength20MG/20ML (1MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalAugust 2009
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.